株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

樹状細胞癌ワクチンの世界市場:投薬量・価格・治験の動向見通し

Global Dendritic Cell Cancer Vaccine Market Dosage Price and Clinical Trials Outlook 2024

発行 KuicK Research 商品コード 322277
出版日 ページ情報 英文 255 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=111.57円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
樹状細胞癌ワクチンの世界市場:投薬量・価格・治験の動向見通し Global Dendritic Cell Cancer Vaccine Market Dosage Price and Clinical Trials Outlook 2024
出版日: 2018年03月21日 ページ情報: 英文 255 Pages
概要

当レポートでは、世界の樹状細胞癌ワクチン市場について分析し、製品の概要や作用機序・効能、製品価格・投薬量の見通し、市場の推移と最新情勢、主な上市済み製品の概略と相互比較、治験パイプラインの概況 (全63製品:企業別・症状別・相別)、主要企業のプロファイルといった情報を取りまとめてお届けいたします。

第1章 樹状細胞がんワクチン:序論

  • 樹状細胞がんワクチンの略史
  • 樹状細胞がんワクチン:革命的ながん治療薬

第2章 免疫系・がんにおける樹状細胞の役割

  • 樹状細胞:ヒトの免疫系に不可欠な部分
  • 樹状細胞媒介性免疫の、がんに対する効果

第3章 樹状細胞がんワクチンの作用機序

  • 樹状細胞ワクチンの製造プロセス
  • がん細胞に対する樹状細胞ワクチンの作用機序

第4章 認証・上市済み樹状細胞がんワクチン:効能、入手可能性、価格、投薬量の分析

  • Provenge
  • Apceden (Apceden-L、Apceden-O、Apceden-C、Apceden-P)
  • CreaVax RCC

第5章 上市済み樹状細胞がんワクチンの臨床考察

  • シプリューセル-T (Provenge)
  • 樹状細胞ワクチン (CreaVax-HCC、CreaVax-PC、CreaVax-RCC)
  • 樹状細胞活性化サイトカイン誘導キラー細胞 - Shanghai Jia Fu Medical

第6章 樹状細胞がんワクチン:治験パイプライン上にある有望な候補薬

  • CreaVax-HCC、CreavAX-PC、CreaVax-BC
  • Rocapuldencel-T
  • MelCancerVac
  • Apceden (Apceden-GBM, Apceden-RCC)
  • Vaccell

第7章 Provengeと他の治療薬の比較分析:前立腺がんの場合

  • Provenge 対 Jevtana
  • Provenge 対 Zytiga

第8章 樹状細胞がんワクチンの市場機会:地域別の分析

  • 北米
  • インド
  • 韓国
  • 日本

第9章 樹状細胞がんワクチンと他のがん治療薬との併用療法

  • 放射線治療との併用
  • モノクローナル抗体との併用

第10章 世界の樹状細胞がんワクチン市場の現状

  • 世界市場の傾向
  • 地域市場の考察

第11章 各種がんに対する、将来有望な樹状細胞ワクチン

  • 第III相の黒色腫向け樹状細胞ワクチン
  • 急性骨髄性白血病向け樹状細胞ワクチン
  • 脳腫瘍向け樹状細胞ワクチン

第12章 世界の樹状細胞がんワクチン市場のダイナミクス

  • 良好な市場パラメーター
  • 市場成長に関する課題

第13章 世界の樹状細胞がんワクチン市場の将来予測

  • 将来の技術進歩
  • がん有病者の増加に伴う、大規模な標的患者ベースの出現見通し

第14章 樹状細胞がんワクチンの治験パイプライン:概要

第15章 樹状細胞がんワクチンの治験パイプライン:企業別・症状別・相別

  • 未確認
  • 研究
  • 前臨床
  • 臨床
  • 第I相
  • 第I/II相
  • 第II相
  • 第II/III相
  • 第III相

第16章 競争環境

  • 3M Company
  • Activartis
  • Argos Therapeutics
  • Batavia Bioservices
  • Bellicum Pharmaceuticals
  • Creagene
  • DanDrit Biotech
  • DCPrime
  • Dendreon Corporation
  • Elios Therapeutics
  • ImmunoCellular Therapeutics
  • Immunicum
  • Kiromic
  • Medigene
  • Merck
  • Northwest Biotherapeutics
  • Glaxo Smith Kline
  • ImmunoCellular Therapeutics
  • SOTIO
  • Tella Incorporation
  • Theravectys
  • Vaxil BioTherapeutics
目次

“Global Dendritic Cell Cancer Vaccine Market Dosage Price & Clinical Trials Outlook 2024” Report Highlight:

  • Role of Dendritic Cells in Immune System & Cancer
  • Price & Dosage Analysis of Marketed Dendritic Cell Cancer Vaccine
  • Availability & Efficacy Analysis
  • Marketed Dendritic Cell Cancer Vaccines Clinical Insight: 3 Vaccines
  • Comparative Assessment of Provenge v/s other Key Therapeutics
  • Dendritic Cell Cancer Vaccines Clinical Pipeline by Company, Indication & Phase: 63 Vaccines

Conventional therapies like surgery, radiotherapy and chemotherapies are the initial approaches for treating cancer. However, several researchers indicated that these conventional therapies are unable to treat cancer from its root cause and also produce many adverse effects thus, cannot be considered as a future of cancer therapy. Further findings demonstrated that cancer cells directly affect T-cells of the immune system and suppresses the immune activity against it resulting in uninhibited growth of cancer cells. Such incidences triggered the era of modern cancer therapy.

Advances in cellular technologies initiated the research towards exploitation of immune cells for the development of advanced vaccines for treating cancer. One of the cells which are found to be the most attractive target for developing therapeutic vaccines are Dendritic cells as they have the ability to present multiple antigens which are most suited to be a therapy for a multi-cause disease like cancer.

Dendritic cell cancer vaccines have gained significant importance in the market with the approval of first dendritic cell cancer vaccine for metastatic prostate cancer called Provenge. Provenge was approved almost a decade ago and has generated high revenues for the pharmaceutical companies. Dendritic cell vaccines became one of the most promising approaches as it works by boosting up the immune system which in turn will cause no or minimal side effects. Furthermore, cancer is disease with multiple causes and risk factors; researchers stated that instead of preventive vaccines, effective therapeutic vaccines can be developed to treat cancer.

Followed by the approval of Provenge, several similar products were developed for other indications in different regions of the world including CreaVax in South Korea for prostate and kidney cancer and Apceden in India for multiple solid tumors. Additionally, a wide range of dendritic cell vaccines entered in different phases of clinical pipeline such as Vaccell in Japan, TAP Cells in Chile, MelCancerVac in North America and Rocapuldencel-T in US etc. All these dendritic cell cancer vaccines are expected to be approved and commercialized and enhance the Global Dendritic cell vaccine market.

Dendritic cell vaccine is the fastest growing segment of cancer vaccine market with other classes of vaccine like peptide vaccines, HPV vaccine, HBV vaccines etc. Dendritic cell vaccines are more specific for treating cancer while others are limited to the treatment of chronic conditions which can cause cancer. Additionally, development of dendritic cell vaccine has been one of the fastest growing sectors amongst all and has resulted in a strong clinical pipeline with more than 60 products in different phases of clinical trials.

Moreover dendritic cell vaccines are unique of its kind which is specifically approved for advanced stages of cancer. Lack of availability of targeted therapies for advance stage of diseases, highly unmet medical needs of metastatic cancer patients indicates exponential rise in the demand for dendritic cell cancer vaccines. Furthermore, commercial successes of Provenge which is available in more than 35 countries; CreaVax in South Korea due to large target patient base has resulted in significant growth of the market.

Increasing prevalence of cancer around the globe will fuel the commercial success of unique dendritic cell vaccines. For instance, in 2018 more than 70000 and 120000 people are expected to be affected by renal cell carcinoma in US and Europe respectively which will result in great market success of Rocapuldencel-T in the coming future. Additionally, nearly 1 Million new incidences of cancer are expected to occur in Japan in 2018 which will fuel the dendritic cell cancer vaccine market in this region.

Moreover, dendritic cell vaccines are considered to be the future of cancer therapy. With the advancement in technology and better understanding of cancer cells, dendritic cells can be used as a preventive measure in the coming future. Additionally, dendritic cell cancer vaccines are one of the safest methods to treat cancer as they boost patient's own immune system by presenting and activating specific antigens at the tumor site. Additionally, presence of a wide range of antigens in human immune system and cancer cells provides opportunities for the development of a wide range of unique products.

Table of Contents

1. Prologue to Dendritic Cell Cancer Vaccine

  • 1.1. Historical Overview of Dendritic Cell Cancer Vaccine
  • 1.2. Dendritic Cell Vaccines: A Revolutionary Cancer Therapy

2. Role of Dendritic Cells in Immune System & Cancer

  • 2.1. Dendritic Cell: Integral Part of Human Immune System
  • 2.2. Effects of Cancer on Dendritic Cell Mediated Immunity

3. Mechanism of Action of Dendritic Cell Cancer Vaccines

  • 3.1. Process Involved in Manufacturing Dendritic Cell Vaccine
  • 3.2. Understanding Working Mechanism of Dendritic Cell Vaccine against Cancer Cells

4. Commercially Approved Dendritic Cell Cancer Vaccine: Efficacy, Availability, Price & Dosage Analysis

  • 4.1. Provenge
    • 4.1.1. Clinical Efficacy
    • 4.1.2. Availability, Dosage & Treatment Schedule
    • 4.1.3. Treatment Cost Analysis
    • 4.1.4. Manufacturing Cost & Market Worth
  • 4.2. Apceden (Apceden-L, Apceden-O, Apceden-C, Apceden-P)
    • 4.2.1. Clinical Efficacy
    • 4.2.2. Availability, Dosage & Treatment Schedule
  • 4.3. CreaVax RCC
    • 4.3.1. Availability, Dosage & Treatment Schedule
    • 4.3.2. Manufacturing Cost Process & Involved Technologies

5. Marketed Dendritic Cell Cancer Vaccines Clinical Insight

  • 5.1. Sipuleucel-T (Provenge)
  • 5.2. Dendritic Cell Vaccine (CreaVax-HCC, CreaVax-PC & CreaVax-RCC)
  • 5.3. Dendritic Cell-Activated Cytokine-Induced Killer Cells - Shanghai Jia Fu Medical

6. Promising Candidates in Dendritic Cell Cancer Vaccine in Clinical Pipeline

  • 6.1. CreaVax-HCC, CreavAX-PC, CreaVax-BC
  • 6.2. Rocapuldencel-T
  • 6.3. MelCancerVac
  • 6.4. Apceden (Apceden-GBM, Apceden-RCC)
  • 6.5. Vaccell

7. Comparative Assessment of Provenge v/s other Therapeutics for Prostate Cancer

  • 7.1. Provenge v/s Jevtana
    • 7.1.1. Clinical Efficacy
    • 7.1.2. Treatment Course & Dosage
    • 7.1.3. Therapy Price Analysis
  • 7.2. Provenge v/s Zytiga
    • 7.2.1. Clinical Efficacy
    • 7.2.2. Treatment Course & Dosage
    • 7.2.3. Therapy Price Analysis

8. Dendritic Cell Cancer Vaccine Market Opportunity Regional Analysis

  • 8.1. North America
  • 8.2. India
  • 8.3. South Korea
  • 8.4. Japan

9. Dendritic Cell Cancer Vaccine Combination Therapy with other Cancer Therapies

  • 9.1. Dendritic Cell Cancer Vaccine with Radiotherapy
  • 9.2. Dendritic Cell Cancer Vaccine with Monoclonal Antibodies

10. Global Dendritic Cell Cancer Vaccine Current Market Overview

  • 10.1. Global Dendritic Cell Cancer Vaccine Market Trends
  • 10.2. Global Dendritic Cell Vaccine Market Regional Insight
    • 10.2.1. Scope of Dendritic Cell Vaccine Market by Ongoing Researches & Available Advanced Therapies by Region
    • 10.2.2. Scope of Dendritic Cell Vaccine Market by Investments for from Different Sectors
    • 10.2.3. Scope of Reimbursement of Dendritic Cell Cancer Therapy

11. Promising Future of Dendritic Cell Vaccines in Various Cancer

  • 11.1. Dendritic Cell Vaccine in Stage-III Melanoma
  • 11.2. Dendritic Cell Vaccine in Acute Myeloid Leukemia
  • 11.3. Dendritic Cell Vaccine in Brain Tumor

12. Global Dendritic Cell Cancer Vaccine Market Dynamics

  • 12.1. Favorable Market Parameters
  • 12.2. Market Growth Challenges

13. Global Dendritic Cell Cancer Vaccine Market Future Forecast

  • 13.1. Technical Advancements in Dendritic Cell Cancer Vaccine in Future
  • 13.2. Increase in Prevalence of Cancer Providing a Large Target Patient Base for Dendritic Cell Cancer Vaccine in Future

14. Global Dendritic Cell Cancer Vaccines Clinical Pipeline Overview

15. Global Dendritic Cell Cancer Vaccines Clinical Pipeline by Company, Indication & Phase

  • 15.1. Unknown
  • 15.2. Research
  • 15.3. Preclinical
  • 15.4. Clinical
  • 15.5. Phase-I
  • 15.6. Phase-I/II
  • 15.7. Phase-II
  • 15.8. Phase-II/III
  • 15.9. Phase-III

16. Competitive Landscape

  • 16.1. 3M Company
  • 16.2. Activartis
  • 16.3. Argos Therapeutics
  • 16.4. Batavia Bioservices
  • 16.5. Bellicum Pharmaceuticals
  • 16.6. Creagene
  • 16.7. DanDrit Biotech
  • 16.8. DCPrime
  • 16.9. Dendreon Corporation
  • 16.10. Elios Therapeutics
  • 16.11. ImmunoCellular Therapeutics
  • 16.12. Immunicum
  • 16.13. Kiromic
  • 16.14. Medigene
  • 16.15. Merck
  • 16.16. Northwest Biotherapeutics
  • 16.17. Glaxo Smith Kline
  • 16.18. ImmunoCellular Therapeutics
  • 16.19. SOTIO
  • 16.20. Tella Incorporation
  • 16.21. Theravectys
  • 16.22. Vaxil BioTherapeutics

List of Figures

  • Figure 1-1: Milestones in the History of Dendritic Cell Cancer Vaccine Development
  • Figure 2-1: Dendritic Cell in Human Immune System
  • Figure 2-2: Effects of Tumor Cell in Dendritic Cell Dysfunction Leading to Tumor Progression
  • Figure 3-1: Process of Harvesting Dendritic Cell to Develop Vaccines
  • Figure 3-2: General Mechanism of Action of Dendritic Cell Vaccine
  • Figure 4-1: Provenge: Efficacy on the Basis of Clinical Trials
  • Figure 4-2: Provenge - Number of Autologous CD54+ Activated Cells (Million)
  • Figure 4-3: Provenge - Dosage Administration (Minutes)
  • Figure 4-4: Provenge - Average Duration of Therapy
  • Figure 4-5: Provenge - Therapy Cost Analysis (US$/Infusion), 2018
  • Figure 4-6: Provenge - Average Cost (US$/Patient), 2018
  • Figure 4-7: Provenge - Therapy Cost Analysis (US$/Treatment Course), 2018
  • Figure 4-8: Provenge - Company's Expenditure in Drug Development & Therapy Market Value (US$ Billion)
  • Figure 4-9: Apceden - Median Progression-Free Survival in Patients with Solid Tumors (Number of Months), 2018
  • Figure 4-10: Apceden - Median Progression Free Survival in Patients with Progressive Solid Tumors (Number of Months), 2018
  • Figure 4-11: Apceden v/s Provenge - Adverse Side Effects (%), 2018
  • Figure 4-12: Apceden - Availability of Vial & Vials Required in Apceden Therapy, 2018
  • Figure 4-13: Apceden - Intervals Between Multiple Doses of Treatment
  • Figure 4-14: CreaVax RCC - Approval Analysis by Phase (Year)
  • Figure 4-15: CreaVax RCC - Treatment Course Duration (Weeks), 2018
  • Figure 4-16: CreaVax RCC - Vial Composition Analysis (mL/Dose & Number of Cells/Dose), 2018
  • Figure 4-17: South Korea - CreaVax RCC Patent Cost (US$)
  • Figure 4-18: South Korea - Pharmaceutical Compositions comprising Dendritic Cell Patent Cost (US$)
  • Figure 7-1: Provenge v/s Jevtana - Median Progression Free Survival (Months)
  • Figure 7-2: Provenge v/s Jevtana - Overall Survival (Months)
  • Figure 7-3: Provenge v/s Jevtana - Discontinuation of Treatment in Patients due to Adverse Effects (%)
  • Figure 7-4: Provenge v/s Jevtana - Average Treatment Cycles in Complete Therapy (By Number)
  • Figure 7-5: Provenge v/s Jevtana - Price Analysis (US$/Unit), 2018
  • Figure 7-6: Provenge v/s Jevtana - Price Analysis (US$/Infusion), 2018
  • Figure 7-7: Provenge v/s Jevtana - Average Treatment Cost Analysis (US$), 2018
  • Figure 7-8: Provenge v/s Zytiga - Median Progression Free Survival (Months)
  • Figure 7-9: Provenge v/s Zytiga - Therapy Cost Analysis (US$), 2018
  • Figure 8-1: Global - Rocapuldencel-T Market Opportunity Analysis by Epidemiology of Renal Cell Carcinoma (Number of patients), 2018
  • Figure 8-2: India - Average Lung Cancer Prevalence per Year
  • Figure 8-3: India - Lung Cancer Prevalence by Stage (%), 2018
  • Figure 8-4: India - Apceden Market Opportunity by Epidemiology of Lung Cancer (Number of Patients), 2014-2018
  • Figure 8-5: India - Apceden Market Opportunity by Epidemiology of Ovarian Cancer (Number of Patients), 2014-2018
  • Figure 8-6: India - Apceden Market Opportunity by Epidemiology of Colorectal Cancer (Number of Patients), 2014-2018
  • Figure 8-7: India - Apceden Market Opportunity by Epidemiology of Prostate Cancer (Number of Patients), 2014-2018
  • Figure 8-8: South Korea - Renal Cell Carcinoma Population by Stage of Cancer, (%), 2018
  • Figure 8-9: South Korea - CreaVax RCC Market Opportunity by Renal Cancer Epidemiology (Number of Patients), 2014-2018
  • Figure 8-10: South Korea - Renal Cell Carcinoma Prevalence in Male Population by Number, 2014-2018
  • Figure 8-11: South Korea - Renal Cell Carcinoma Prevalence in Female Population by Number, 2014-2018
  • Figure 8-12: South Korea - Renal Cancer Prevalence by Gender, 2018
  • Figure 8-13: Japan - Epidemiology of Cancer by Gender (%), 2018
  • Figure 8-14: Japan - Epidemiology of Cancer (Number of Patients), 2018
  • Figure 8-15: Japan - Vaccell Market Opportunity by Epidemiology of Pancreatic Cancer by Gender (%), 2018
  • Figure 8-16: Japan - Vaccell market Opportunity by Epidemiology of Pancreatic Cancer (Number of Patients), 2018
  • Figure 8-17: Japan - Vaccell Market Opportunity by Epidemiology of Gall Bladder & Biliary Cancer by Gender (%), 2018
  • Figure 8-18: Japan - Vaccell Market Opportunity by Epidemiology of Gall Bladder & Biliary Cancer (Number of Patients), 2018
  • Figure 8 19: Japan - Vaccell Potential Patient Base by New Incidences, 2018
  • Figure 10-1: Global - Scope of Dendritic Cell Cancer Therapy Market by Ongoing Researches
  • Figure 10-2: Global - Scope of Dendritic Cell Cancer Therapy Market by Approved Advanced Therapies
  • Figure 10-3: Global - Scope of Dendritic Cell Vaccine Cancer Therapy Market by Later Phase Clinical Trials
  • Figure 10-4: Global - Number of Advanced Cancer Therapy Research Studies Funded by Non-Profit Organization
  • Figure 12-1: Factors Favoring Global Dendritic Cell Cancer Vaccine Market
  • Figure 13-1: Global - Dendritic Cell Cancer Vaccine Market Opportunity by Prevalence of Cancer (%)
  • Figure 14-1: Global Dendritic Cell Cancer Vaccines Clinical Pipeline by Phase (%), 2018 till 2024
  • Figure 14-2: Global Dendritic Cell Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 till 2024
  • Figure 14-3: Global Dendritic Cell Cancer Vaccines Suspended in Clinical Pipeline by Phase (%), 2018 till 2024
  • Figure 14-4: Global Dendritic Cell Cancer Vaccines Suspended in Clinical Pipeline by Phase (Number), 2018 till 2024
  • Figure 14-5: Global Dendritic Cell Cancer Vaccines Clinical Pipeline by Region/Country (%), 2018 till 2024
  • Figure 14-6: Global Dendritic Cell Cancer Vaccines Clinical Pipeline by Company (%), 2018 till 2024
  • Figure 16-1: Argos Therapeutics- Clinical Pipeline
  • Figure 16-2: Bellicum Pharmaceuticals Clinical Pipeline
  • Figure 16-3: DCPrime Clinical Pipeline
  • Figure 16-4: ImmunoCellular Therapeutics Clinical Pipeline
  • Figure 16-5: Immunicum Clinical Pipeline
  • Figure 16-6: Medigene Clinical Pipeline
  • Figure 16-7: Northwest Biotherapeutics Clinical Pipeline
  • Figure 16-8: SOTIO Clinical Pipeline
Back to Top